Respirology:胸腔积液肺癌患者的临床特征和存活率

2015-02-24 范伟 MedSci原创

背景和目的:胸腔积液肺癌的临床意义很少进行系统性的梳理。本研究的目的是确定肺癌合并胸腔积液患者的患病率,病因和自然历史,以及对他们生存的影响。方法:在我们机构中,对新诊断的超过4年的556例肺癌患者的影像学和临床资料进行回顾分析。结果:肺癌患者包括490例非小细胞肺癌和66例小细胞类型的肺癌。约40%的肺癌患者在他们的疾病过程中伴有胸腔积液。有一半的患者胸腔积液太小可吸取掉。这些积液没有发展到需要

背景和目的:胸腔积液肺癌的临床意义很少进行系统性的梳理。本研究的目的是确定肺癌合并胸腔积液患者的患病率,病因和自然历史,以及对他们生存的影响。

方法:在我们机构中,对新诊断的超过4年的556例肺癌患者的影像学和临床资料进行回顾分析。

结果:肺癌患者包括490例非小细胞肺癌和66例小细胞类型的肺癌。约40%的肺癌患者在他们的疾病过程中伴有胸腔积液。有一半的患者胸腔积液太小可吸取掉。这些积液没有发展到需要胸腔干预。最少积液的患者相比于无胸腔积液的患者预后较差(中位生存期为7.49个月 vs 12.65个月,P<  0.001)。113例进行胸腔穿刺术的患者中小于20%的人有良性积液的病因。保守的胸腔手术(如治疗性的胸腔穿刺引流,胸膜固定术或隧道式的胸腔引流)在94例恶性胸腔积液患者中的79人(84%)上进行。胸腔积液的大小等于或大于一半的胸部面积时则需要进行保守的手术。恶性胸腔积液患者的总生存期为5.49个月。

结论:恶性胸腔积液是肺癌中不良的预后因素,包括最少的不适合吸取的胸腔积液。

原始出处

Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions.  Respirology. 2015 Feb 23. doi: 10.1111/resp.12496.
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    很不错学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-02-25 orthoW

    不错的文章,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-02-25 hbwang006

    明白了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-02-25 hbwang006

    确实,临床见

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1990538, encodeId=ca4a19905384b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 05 14:10:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862882, encodeId=19f61862882d4, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Fri Nov 27 13:10:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1842847, encodeId=ea9c184284ed4, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Oct 12 11:10:00 CST 2015, time=2015-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23715, encodeId=877923e156f, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:33:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17005, encodeId=d3261e005f8, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Wed Feb 25 17:50:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16945, encodeId=80131694519, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16946, encodeId=8cc116946fb, content=确实,临床见, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Wed Feb 25 03:39:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16943, encodeId=5b6416943d2, content=速度~, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db961615658, createdName=weiwei881111, createdTime=Wed Feb 25 00:43:00 CST 2015, time=2015-02-25, status=1, ipAttribution=)]
    2015-02-25 weiwei881111

    速度~

    0

相关资讯

CA Cancer J Clin:2015全球肺癌流行病学调查数据

关键要点: 1. GLOBOCAN2012: 2012年全球约有1.41千万新发癌症病例,其中肺癌发病率为180万,占癌症发病率的13%,是癌症中诊断率最高的病种,也是全球男性、发达国家女性癌症死亡率最高的病种 2. 中国女性中肺癌发病率为20.4/10万,发病率已超过部分女性吸烟率较高的欧洲国家 3. 包括中国在内的东亚国家,50%的肺癌死亡率归结于户外小分子颗粒物的吸入 4. 引起肺癌

Cancer Res:事出有因!吸烟致肺癌转移新发现

肺癌有不同的风险因素,包括石棉、氡的职业暴露、环境暴露与遗传因素等。然而,最重要的因素是吸烟,其中男性的归因风险为80%,女性的归因风险为45%。肺癌的发病率普遍男性高于女性,但目前女性的发病率不断增加,而男性的发病率趋于稳定。约87%的肺癌病例可归因于烟草暴露。吸烟者患肺癌的相对危险度是不吸烟者的24倍。既往吸烟者患肺癌的相对危险性虽然比吸烟者低,但比非吸烟者高。据估计,美国去年死于肺癌的人数超

《原发性肺癌诊疗规范》(2015年版)下载

原发性肺癌(以下简称肺癌)是我国最常见的恶性肿瘤之一。全国肿瘤登记中心2014年发布的数据显示,2010年,我国新发肺癌病例60.59万(男性41.63万,女性18.96万),居恶性肿瘤首位(男性首位,女性第2位),占恶性肿瘤新发病例的19.59%(男性23.03%,女性14.75%)。 肺癌发病率为35.23/10万(男性49.27/10万,女性21.66/10万)。同期,我国肺癌死亡人数为4

Cancer Prev Res:二甲双胍可能还能降低糖尿病患者的肺癌风险

最新研究指出,对于不吸烟的糖尿病患者,降糖药二甲双胍的作用不仅能够控制血糖,还能降低肺癌的患病率。研究结果发表在最新一期美国癌症研究协会旗下的Cancer Prevention Research杂志上。该项研究由加利福尼亚洲奥克兰市Kaiser Permanente研究部科学家Lori Sakoda博士主持。“一些实验室研究和观察性研究提示,二甲双胍可能具有预防癌症的作用。然而,” Lori Sa

Ann Intern Med:低剂量CT扫描采用Lung-RADS标准识别肺癌无优势

低剂量CT(LDCT)扫描适用于肺癌的筛查已经被广受推荐,这主要源于美国国立胸部摄像研究(the National Lung Screening Trial,NLST)证据所支持。最近美国放射学会(American College of Radiology)发布了Lung-RADS标准(Lung-RADS是一种专门针对LDCT的肺癌扫描结果的分级和分类工具)。 为评估Lung-RADS相对于NLS